Lamictal in the Treatment of Post-Herpetic Neuralgia

Phase 3TerminatedNCT00295776

George Washington University

Overview

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Conditions

Neuralgia, Postherpetic

Interventions

Lamictal in the treatment of Post-Herpetic NeuralgiaDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients will be over the age of 18, * Need to have a diagnosis of Post-Herpetic Neuralgia, * Minimum of 4 on the Likert Pain Scale, * If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks Exclusion Criteria: * Currently on any antiepileptic drugs (AED), except for Gabapentin. * Currently taking opioid or unwilling to washout prior to the study, * Pregnant and lactating, * Have active severe systemic disease, * History of Stevens-Johnson syndrome or TEN, * Clinically significant abnormal lab values, * Known drug allergy to Lamictal, * Patients on Fibrates (Tricor and Lopid), * History of major psychiatric disturbance and substance abuse. * Valproate due to increase chances of severe rash, * Lidocaine Patch, * Use of hormonal contraceptives (birth control pills, patch, ring, injection)

Locations (1)

Medical Faculty Associates

Washington D.C., District of Columbia, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.